Cancer

The Assistance Fund Opens New Program for Myeloproliferative Neoplasms

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Myeloproliferative Neoplasms ORLANDO, FLORIDA / ACCESS Newswire…

1 month ago

CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI

SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ -- CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that…

1 month ago

CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI

SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ -- CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that…

1 month ago

CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI

SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ -- CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that…

1 month ago

Teal Health Expands Nationwide, Bringing the Only FDA-Authorized Device for At-Home Cervical Cancer Screening to All 50 States

For the first time ever, women across the U.S. have access to a comfortable, convenient, and accurate at-home cervical cancer…

1 month ago

Teal Health Expands Nationwide, Bringing the Only FDA-Authorized Device for At-Home Cervical Cancer Screening to All 50 States

For the first time ever, women across the U.S. have access to a comfortable, convenient, and accurate at-home cervical cancer…

1 month ago

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026…

1 month ago

Teal Health Expands Nationwide, Bringing the Only FDA-Authorized Device for At-Home Cervical Cancer Screening to All 50 States

For the first time ever, women across the U.S. have access to a comfortable, convenient, and accurate at-home cervical cancer…

1 month ago

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026…

1 month ago

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026…

1 month ago